Next Article in Journal
Optimal Androgen Deprivation Therapy Combined with Proton Beam Therapy for Prostate Cancer: Results from a Multi-Institutional Study of the Japanese Radiation Oncology Study Group
Previous Article in Journal
Immunoglobulin M Paraproteinaemias
Previous Article in Special Issue
Gastric Cancer Staging: Is It Time for Magnetic Resonance Imaging?
Open AccessArticle

Impact of Tumor Localization and Molecular Subtypes on the Prognostic and Predictive Significance of p53 Expression in Gastric Cancer

1
Institute of Pathology, TUM School of Medicine, Technical University of Munich, 81675 Munich, Germany
2
Institute of Pathology and Molecular Diagnostics, University Hospital Augsburg, 86156 Augsburg, Germany
3
Department of Surgery, TUM School of Medicine, Technical University of Munich, 81675 Munich, Germany
4
Institute of Pathology, University of Heidelberg, 69120 Heidelberg, Germany
5
Institute of Pathology, University Medical Center Mainz, JGU-Mainz, 55131 Mainz, Germany
6
Department of General, Visceral and Transplantation Surgery, University of Heidelberg, 69120 Heidelberg, Germany
7
Institute of Medical Informatics, Statistics and Epidemiology, Technical University of Munich, 81675 Munich, Germany
8
Department of Surgery, Klinikum Rosenheim, 83022 Rosenheim, Germany
9
German Cancer Consortium [DKTK], Partner Site Munich, Institute of Pathology, 81675 Munich, Germany
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(6), 1689; https://doi.org/10.3390/cancers12061689
Received: 12 May 2020 / Revised: 10 June 2020 / Accepted: 23 June 2020 / Published: 25 June 2020
(This article belongs to the Special Issue Molecular Mechanisms of Gastric Cancer Development)
We investigated the prognostic and predictive impact of p53 expression for gastric cancer (GC) patients treated without or with preoperative chemotherapy (CTx) and its relationship with specific molecular GC subtypes. Specimens from 694 GC patients (562 surgical resection specimens without or after CTx, 132 biopsies before CTx) were analyzed by p53 immunohistochemistry. High (H) and low (L) microsatellite instability (MSI) and Epstein–Barr virus positivity were determined previously. Our results show that aberrant p53 expression was a negative prognostic factor in uni- and multivariable analysis in the resection specimens cohort (each p < 0.01). Subgroup analysis showed the strongest prognostic effect for patients with distally located tumors or no CTx treatment. In the biopsy cohort before CTx, p53 did not predict response or survival. p53 expression was significantly different among the molecular subtypes in surgical resection and bioptic specimens with strong association of altered p53 with MSI-L. Patients with MSI-H and aberrant p53 showed the worst survival in the biopsy cohort. In conclusion, the prognostic impact of p53 in GC differs according to tumor localization and CTx. Altered p53 is characteristic for MSI-L, and the p53 status in biopsies before CTx delineates MSI-H subtypes with inverse prognostic impact. View Full-Text
Keywords: p53; adenocarcinoma; gastric; gastroesophageal junction; prognosis; neoadjuvant chemotherapy; molecular subtype; microsatellite instability p53; adenocarcinoma; gastric; gastroesophageal junction; prognosis; neoadjuvant chemotherapy; molecular subtype; microsatellite instability
Show Figures

Figure 1

MDPI and ACS Style

Grosser, B.; Kohlruss, M.; Slotta-Huspenina, J.; Jesinghaus, M.; Pfarr, N.; Steiger, K.; Novotny, A.; Gaida, M.M.; Schmidt, T.; Hapfelmeier, A.; Ott, K.; Weichert, W.; Keller, G. Impact of Tumor Localization and Molecular Subtypes on the Prognostic and Predictive Significance of p53 Expression in Gastric Cancer. Cancers 2020, 12, 1689.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop